# Aldeyra Therapeutics, Inc. clinical trials: 35 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials with Aldeyra Therapeutics, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Aldeyra Therapeutics, Inc.: 35 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/aldeyra-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 11, 2026 | NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | Aldeyra Therapeutics, Inc. | Phase 3 | Recruiting | Primary Vitreoretinal Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07402876) |
| November 12, 2024 | NCT06685692 | A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Alcohol Hepatitis | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06685692) |
| July 10, 2024 | NCT06493604 | A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease | Aldeyra Therapeutics, Inc. | Phase 3 | Completed | Dry Eye Disease | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06493604) |
| May 22, 2024 | NCT06424444 | A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease | Aldeyra Therapeutics, Inc. | Phase 3 | Completed | Dry Eye Disease | 421 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06424444) |
| April 29, 2024 | NCT06389214 | A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease | Aldeyra Therapeutics, Inc. | Phase 3 | Completed | Dry Eye Disease | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06389214) |
| February 8, 2023 | NCT05717920 | A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Atopic Dermatitis | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05717920) |
| October 31, 2022 | NCT05599815 | Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome | Aldeyra Therapeutics, Inc. | Phase 2 | Withdrawn | Nephrotic Syndrome | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05599815) |
| August 4, 2022 | NCT05487404 | A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels | Aldeyra Therapeutics, Inc. | Phase 1/2 | Completed | Ethanol Intoxication | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05487404) |
| June 21, 2022 | NCT05424549 | A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Dry Eye Syndromes | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05424549) |
| May 26, 2022 | NCT05392192 | A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Chronic Cough | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05392192) |
| May 26, 2022 | NCT05392179 | A Study in Subjects With Retinitis Pigmentosa | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Retinitis Pigmentosa | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05392179) |
| February 10, 2022 | NCT05234554 | The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis | Aldeyra Therapeutics, Inc. | Phase 3 | Completed | Allergic Conjunctivitis | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05234554) |
| November 1, 2021 | NCT05102409 | An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Dry Eye | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05102409) |
| September 30, 2021 | NCT05062330 | The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease | Aldeyra Therapeutics, Inc. | Phase 3 | Completed | Dry Eye | 361 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05062330) |
| July 21, 2021 | NCT04971031 | A Clinical Trial to Assess Subjects With Dry Eye Disease. | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Dry Eye | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04971031) |
| June 1, 2021 | NCT04908514 | A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Plaque Psoriasis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04908514) |
| April 19, 2021 | NCT04847544 | A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the... | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Covid19 | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04847544) |
| February 3, 2021 | NCT04735393 | A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic... | Aldeyra Therapeutics, Inc. | Phase 3 | Completed | Dry Eye Disease | 757 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04735393) |
| January 28, 2021 | NCT04728711 | A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild... | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Atopic Asthma | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04728711) |
| December 19, 2020 | NCT04674358 | The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease | Aldeyra Therapeutics, Inc. | Phase 2/3 | Completed | Dry Eye, Dry Eye Syndromes | 329 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04674358) |
| December 23, 2019 | NCT04207736 | The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. | Aldeyra Therapeutics, Inc. | Phase 3 | Completed | Allergic Conjunctivitis | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04207736) |
| October 23, 2019 | NCT04136366 | The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy | Aldeyra Therapeutics, Inc. | Phase 3 | Completed | Proliferative Vitreoretinopathy | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04136366) |
| April 16, 2019 | NCT03916042 | A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and... | Aldeyra Therapeutics, Inc. | Phase 2 | Completed | Dry Eye | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03916042) |
| March 19, 2019 | NCT03879863 | The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess... | Aldeyra Therapeutics, Inc. | Phase 3 | Completed | Dry Eye | 422 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03879863) |
| October 17, 2018 | NCT03709121 | A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure... | Aldeyra Therapeutics, Inc. | Phase 1/2 | Completed | Conjunctivitis, Allergic | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03709121) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1/2 | 3 |
| Phase 2 | 18 |
| Phase 2/3 | 1 |
| Phase 3 | 13 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 33 |
| Withdrawn | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dry Eye Syndromes | 13 |
| Conjunctivitis, Allergic | 7 |
| Sjogren-Larsson Syndrome | 2 |
| Dermatitis, Atopic | 1 |
| Eczema | 1 |
| Nephrotic Syndrome | 1 |
| Nephrosis, Lipoid | 1 |
| Glomerulosclerosis, Focal Segmental | 1 |
| Renal Insufficiency, Chronic | 1 |
| Chronic Cough | 1 |
| Cough | 1 |
| Inflammation | 1 |
| Uveitis | 1 |
| Uveitis, Anterior | 1 |
| Ichthyosis | 1 |
| Rhinitis, Allergic, Seasonal | 1 |
| COVID-19 | 1 |
| Hepatitis, Alcoholic | 1 |
| Vitreoretinopathy, Proliferative | 1 |
| Retinal Detachment | 1 |
| Retinitis Pigmentosa | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Stock brokers in the United States](https://specstream.ai/data/businesses/stock-brokers/united-states)
- [Hazardous waste disposal companies in the United States](https://specstream.ai/data/businesses/hazardous-waste-disposal-companies/united-states)
- [American restaurants in the United States](https://specstream.ai/data/businesses/american-restaurants/united-states)
- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Carpet cleaning companies in the United States](https://specstream.ai/data/businesses/carpet-cleaning-companies/united-states)
- [Publishers in the United States](https://specstream.ai/data/businesses/publishers/united-states)
